PDE4A and neoplasm: Roflumilast was the first PDE4 inhibitor approved by the FDA for the prevention of chronic obstructive pulmonary disease (COPD) exacerbations [31] and effectively inhibits tumor proliferation and growth in ovarian cancer [32].